Evidence map›Paper›PMID 41775859›Full record

ArticleNPJ cardiovascular health2025

Collagen-targeted tracers for molecular imaging of atrial fibrosis and sensitive detection of atrial fibrillation.

Be'eri Niego, Christoph E Hagemeyer, Bianca Jupp, Asif Noor, Paul S Donnelly, Rong Xu, Thirimadura V H Mendis, Yi Ching Chen, Irena Carmichael, Julie R McMullen and 1 more

Abstract read
In one paragraph

Article in NPJ cardiovascular health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Be'eri Niego *NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia. beeri.niego@monash.edu.
Christoph E Hagemeyer *NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Bianca JuppMonash Biomedical Imaging, Monash University, Melbourne, VIC, Australia.
Asif NoorSchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, Australia.
Paul S DonnellySchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, Australia.
Rong XuNanoBiotechnology Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Thirimadura V H MendisNanoBiotechnology Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Yi Ching ChenNanoBiotechnology Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Irena CarmichaelMonash Micro Imaging, Alfred Research Alliance, Monash University, Melbourne, VIC, Australia.
Julie R McMullenHeart Research Institute, The University of Sydney, Sydney, NSW, Australia.
Karen AltNanoTheranostics Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.

Funding

Australian Research Council 2011853National Health and Medical Research Council GNT1120129National Health and Medical Research Council GNT1140465National Heart Foundation of Australia 106859NSW Health, Australia Cardiovascular Research Capacity Program - Research Leadership GrantThe Baker Foundation, Australia Baker Fellowship
6 · The paper itself

Abstract

Atrial fibrillation (AF), often accompanied by atrial fibrosis, is challenging to diagnose sub-clinically and reverse once established. Molecular imaging targeting excess atrial collagen may enable earlier detection of atrial fibrosis and its associated arrhythmias. We used the collagen I-binding peptide EP-3533 and our novel 'T-peptide' targeting matrix metalloproteinases-2-digested collagen IV to image interstitial atrial fibrosis, AF and heart failure (HF) that develop in the double transgenic mouse model dnPI3K-Mst1 (termed 'AF + HF'). Ex vivo and in vivo imaging were performed using near-infrared scans and positron emission tomography (PET) with probes conjugated to Cyanine5.5 and copper-64, respectively. Both tracers significantly accumulated in fibrotic atria compared to non-transgenic controls, with specific T-peptide uptake relative to a mutated 'S-peptide'. Pharmacokinetic profiling demonstrated good tracer plasma stability and fast renal clearance. These results highlight the potential of collagen-targeted peptide tracers, particularly the disease stage-sensitive T-peptide, to improve diagnosis and monitoring of atrial fibrosis and AF.

Identifiers

PMID41775859
PMCPMC12912425

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.